Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 6/20 | 0.58 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.58 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.58 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.54 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.45 |
| ▸ | MPO | P05164 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12475193 | 1.00 | P2RX1 (0.58) | P2RX1P2RX4P2RX7TMPRSS4GPR35 | |
| SCHEMBL11010708 | 0.88 | P2RX1 (0.58) | P2RX1P2RX4P2RX7TMPRSS4MAPT | |
| SCHEMBL28345196 | 0.86 | P2RX1 (0.57) | P2RX1P2RX4P2RX7TMPRSS4GPR35 | |
| SCHEMBL9652246 | 0.83 | ALOX5 (0.54) | P2RX1MAPTLMNAMEN1KMT2A | |
| SCHEMBL15542587 | 0.82 | TGM2 (0.56) | P2RX1P2RX4P2RX7TMPRSS4GPR35 | |
| SCHEMBL5833345 | 0.81 | GPR35 (0.66) | P2RX1P2RX4P2RX7TMPRSS4GPR35 | |
| SCHEMBL31609063 | 0.81 | MEN1 (0.69) | P2RX1P2RX4P2RX7TMPRSS4MAPT | |
| SCHEMBL11010886 | 0.80 | TRPV1 (0.67) | P2RX1P2RX4P2RX7MAPTLMNA | |
| SCHEMBL15077333 | 0.80 | P2RX1 (0.52) | P2RX1P2RX4P2RX7TMPRSS4MAPT | |
| Nitric Acid SCHEMBL1673 | 0.80 | P2RX1 (0.51) | P2RX1P2RX4P2RX7TMPRSS4GPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616443-A1 | PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS | Exelixis, Inc. (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20130165440-A1 | JAK1 Inhibitors | EXELIXIS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| WO-2012037132-A1 | PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS | EXELIXIS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165440-A1 | JAK1 Inhibitors | JAK1, JAK2, JAK3 | P2RX1 1196/4885P2RX4 2542/4885P2RX7 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.